Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Curran

Showing results (941-950 of 965) with videos related to

Pageof 97
Sort By:
The Journal of Clinical Investigation|March 23, 2023
Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplantSusan E Prockop, Aisha Hasan, Ekaterina Doubrovina, et al.
The Journal of Clinical Investigation|November 6, 2019
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantationSusan Prockop, Ekaterina Doubrovina, Stephanie Suser, et al.
Lancet (London, England)|December 10, 2019
Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trialFrank A Vicini, Reena S Cecchini, Julia R White, et al.
Morbidity and Mortality Weekly Report. Surveillance Summaries (Washington, D.C. : 2002)|January 17, 2003
Adult blood lead epidemiology and surveillance--United States, 1998-2001Robert J Roscoe, Wayne Ball, John J Curran, et al.
Blood Advances|August 8, 2022
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortiumHeather E Stefanski, Anne Eaton, Christina Baggott, et al.
Blood Advances|November 18, 2021
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium ReportVanessa A Fabrizio, Christine L Phillips, Adam Lane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2022
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic LeukemiaLiora M Schultz, Anne Eaton, Christina Baggott, et al.
The New England Journal of Medicine|June 4, 2025
Omitting Regional Nodal Irradiation after Response to Neoadjuvant ChemotherapyEleftherios P Mamounas, Hanna Bandos, Julia R White, et al.
Blood Advances|November 17, 2021
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapyVanessa A Fabrizio, Jaap Jan Boelens, Audrey Mauguen, et al.
Blood Advances|May 17, 2022
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemiaAmy Moskop, Lauren Pommert, Christina Baggott, et al.
Pageof 97

Showing results (941-950 of 965) with videos related to

Sort By:
Pageof 97
The Journal of Clinical Investigation|March 23, 2023
Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplantSusan E Prockop, Aisha Hasan, Ekaterina Doubrovina, et al.
The Journal of Clinical Investigation|November 6, 2019
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantationSusan Prockop, Ekaterina Doubrovina, Stephanie Suser, et al.
Lancet (London, England)|December 10, 2019
Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trialFrank A Vicini, Reena S Cecchini, Julia R White, et al.
Morbidity and Mortality Weekly Report. Surveillance Summaries (Washington, D.C. : 2002)|January 17, 2003
Adult blood lead epidemiology and surveillance--United States, 1998-2001Robert J Roscoe, Wayne Ball, John J Curran, et al.
Blood Advances|August 8, 2022
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortiumHeather E Stefanski, Anne Eaton, Christina Baggott, et al.
Blood Advances|November 18, 2021
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium ReportVanessa A Fabrizio, Christine L Phillips, Adam Lane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2022
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic LeukemiaLiora M Schultz, Anne Eaton, Christina Baggott, et al.
The New England Journal of Medicine|June 4, 2025
Omitting Regional Nodal Irradiation after Response to Neoadjuvant ChemotherapyEleftherios P Mamounas, Hanna Bandos, Julia R White, et al.
Blood Advances|November 17, 2021
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapyVanessa A Fabrizio, Jaap Jan Boelens, Audrey Mauguen, et al.
Blood Advances|May 17, 2022
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemiaAmy Moskop, Lauren Pommert, Christina Baggott, et al.
Pageof 97